Might biologics serve to interrupt the atopic march?

The atopic march was described more than 20 years ago on the basis of initial observations, and it is now seen in prospective studies. The concept has evolved and is now considered to be the progression of atopic dermatitis to other atopic conditions, including asthma, allergic rhinitis, food allerg...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 151; no. 3; pp. 590 - 594
Main Authors Spergel, Jonathan M., Du Toit, George, Davis, Carla M.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.03.2023
Subjects
allergic rhinitis
Asthma
Atopic dermatitis
atopic march
Biological Products
biologics
Dermatitis, Atopic
Eosinophilic Esophagitis
food allergy
Humans
Prospective Studies
T2 pathway
FLG
AD
OR
biologics
TSLP
asthma
food allergy
PARK
Atopic dermatitis
atopic march
eosinophilic esophagitis
T2 pathway
allergic rhinitis
FA
T2
Online AccessGet full text

Cover

More Information
Summary:The atopic march was described more than 20 years ago on the basis of initial observations, and it is now seen in prospective studies. The concept has evolved and is now considered to be the progression of atopic dermatitis to other atopic conditions, including asthma, allergic rhinitis, food allergy, and eosinophilic esophagitis in a nonlinear fashion. The progression can include some or all of the aforementioned atopic conditions. The pathogenesis is part of the classic type 2 inflammatory process involving IL-4, IL-5, and IL-13 preceded by induction of the alarmins (thymic stromal lymphopoietin, IL-33, and IL-25), leading to production of IgE in a genetically predisposed individual. The development of new biologics that interact with T2 pathway represent possible ways to prevent or modify the atopic march.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2023.01.001